<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67001">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01734239</url>
  </required_header>
  <id_info>
    <org_study_id>V110-018</org_study_id>
    <nct_id>NCT01734239</nct_id>
  </id_info>
  <brief_title>A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumococcal Vaccine (V110) in Participants From the Russian Population (V110-018 AM1)</brief_title>
  <official_title>A Phase III, Open-Label Clinical Trial to Study the Safety and Immunogenicity of V110 in Subjects 50 Years of Age and Older and in Subjects 2 to 49 Years of Age at Increased Risk for Pneumococcal Disease, From the Russian Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>Russia: Pharmacological Committee, Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if Pneumococcal Vaccine (V110) is safe and
      immunogenic in participants from the Russian population who are 50 years of age and older or
      2 to 49 years of age and at increased risk for pneumococcal disease
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Geometric Mean Concentration of Antibodies to Pneumococcal Serotypes Contained in the Vaccine</measure>
    <time_frame>Day 28 after vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with ≥2-fold Change from Baseline in Antibodies to Pneumococcal Serotypes Contained in the Vaccine</measure>
    <time_frame>Day 28 after vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Elevated Body Temperature (≥37.6°C axillary, ≥38.0°C oral or equivalent)</measure>
    <time_frame>Up to 5 days after vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Solicited Injection-Site Reactions (Redness, Swelling, Pain/Tenderness)</measure>
    <time_frame>Up to 14 days after vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Serious Adverse Experiences</measure>
    <time_frame>Up to 28 days after vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Pneumococcal Disease</condition>
  <arm_group>
    <arm_group_label>V110 Vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single, 0.5-mL intramuscular injection of V110 on Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V110</intervention_name>
    <description>Vaccine contains 25 µg of each of the 23 pneumococcal polysaccharides serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F</description>
    <arm_group_label>V110 Vaccination</arm_group_label>
    <other_name>PNEUMOVAX™ 23</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For participants 50 years of age or older: any underlying chronic illness must be in
             stable condition

          -  For participants 2 to 49 years of age: participant has an increased risk for
             pneumococcal disease as a result of one of the following: chronic cardiovascular
             disease, chronic pulmonary disease, diabetes mellitus, alcoholism, chronic liver
             disease, cerebrospinal fluid leaks, functional or anatomic asplenia, sickle cell
             anemia, living in a special environment or social setting such as crowded, closed
             communities

          -  Male, or female not of reproductive potential, or female of reproductive potential
             who agrees to remain abstinent or to use 2 acceptable methods of contraception
             through 6 weeks after study vaccination

        Exclusion Criteria:

          -  Received prior vaccination with pneumococcal vaccine

          -  Has known or suspected immune dysfunction or conditions associated with
             immunosuppression, or is receiving immunosuppressive chemotherapy, including
             long-term systemic corticosteroids

          -  Has history of autoimmune disease

          -  Received a licensed live virus vaccine within 3 months before or is scheduled within
             3 months after study vaccination

          -  Received a licensed inactivated vaccine within 28 days before or is scheduled within
             28 days after study vaccination

          -  Received an investigational drug or other investigational vaccine within 2 months
             before or is scheduled within 28 days after study vaccination (3 months if a live
             virus vaccine)

          -  Received any blood product or immunoglobulin preparation within 6 months before or 28
             days after study vaccination

          -  Hospitalized for acute illness within 3 months before study vaccination

          -  Is a pregnant woman or nursing mother

          -  History of invasive pneumococcal disease or of other culture-positive pneumococcal
             disease

          -  History of fever illness within 3 days before study vaccination

          -  Received antibiotic therapy for any acute illness within 7 days before study
             vaccination

          -  Hypersensitivity to any components of the vaccine, including phenol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Russian Federation</country>
  </removed_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 13, 2013</lastchanged_date>
  <firstreceived_date>November 21, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
